Evaluation of Lenalidomide (CC-5013) and Prednisone as a Therapy for Patients With Myelofibrosis (MF)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 May 2017
At a glance
- Drugs Lenalidomide (Primary) ; Prednisone (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- 11 May 2017 Planned primary completion date changed from 1 Sep 2018 to 1 Jul 2019.
- 30 Mar 2016 Status changed from recruiting to active, no longer recruiting, according to ClinicalTrials.gov record.
- 09 Mar 2016 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2018 as per ClinicalTrials.gov record.